Don't Reject Bio TransplantBy
Although its products are still in early development, BioTransplant (BTRN) has been attracting big believers. This biotech's pharmaceuticals use technologies that reeducate the immune system to accept donor cells, tissues, and organs. "There is an overwhelming need for a new approach in transplant-rejection therapy, which BTRN is well-positioned to deliver," says Joel Sendek, an analyst at Lazard Freres.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.